Patients receiving allogeneic BMT on medical treatment for AA or with unresponsive AA or clonal evolution to MDS or AML
| BMT or medical treatment for AA, MDS, or AML . | Number (%) . |
|---|---|
| Allogeneic BMT | 46 |
| Reason for BMT: | |
| AA | 38 |
| MDS | 4 |
| AML | 3 |
| Lymphoma | 1 |
| Medical therapy for AA | 58 |
| Cyclosporine | 39 |
| Tacrolimus | 3 |
| Eltrombopag | 7 |
| Oxymetholone | 6 |
| Danazol | 1 |
| Cyclosporine and eltrombopag | 1 |
| Cyclosporine and danazol | 1 |
| Clonal evolution or unresponsive AA (no transplantation) | 16 |
| Unresponsive/progressive AA | 2 |
| MDS | 5 |
| AML | 9 |
| Total | 120 |
| BMT or medical treatment for AA, MDS, or AML . | Number (%) . |
|---|---|
| Allogeneic BMT | 46 |
| Reason for BMT: | |
| AA | 38 |
| MDS | 4 |
| AML | 3 |
| Lymphoma | 1 |
| Medical therapy for AA | 58 |
| Cyclosporine | 39 |
| Tacrolimus | 3 |
| Eltrombopag | 7 |
| Oxymetholone | 6 |
| Danazol | 1 |
| Cyclosporine and eltrombopag | 1 |
| Cyclosporine and danazol | 1 |
| Clonal evolution or unresponsive AA (no transplantation) | 16 |
| Unresponsive/progressive AA | 2 |
| MDS | 5 |
| AML | 9 |
| Total | 120 |